Microbot Medical, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59503A2042
USD
2.46
0.25 (11.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Microbot Medical, Inc. stock-summary
stock-summary
Microbot Medical, Inc.
Pharmaceuticals & Biotechnology
Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms, ViRob, TipCAT and Liberty, including certain CardioSert assets, are comprised of proprietary technologies. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCSTM) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot. TipCAT is a disposable self-propelled locomotive device. Liberty is a disposable robotic system.
Company Coordinates stock-summary
Company Details
25 RECREATION PARK DR SUITE 108 , HINGHAM MA : 02043
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (3.13%)

Foreign Institutions

Held by 15 Foreign Institutions (0.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Harel Gadot
Chairman of the Board, President, Chief Executive Officer
Mr. Yoseph Bornstein
Independent Director
Mr. Scott Burell
Independent Director
Mr. Prattipati Laxminarain
Independent Director
Mr. Martin Madden
Independent Director
Ms. Aileen Stockburger
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 205 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.07

stock-summary
Return on Equity

-41.86%

stock-summary
Price to Book

6.75